 GAITHERSBURG, Md., May 31, 2022 GLOBE NEWSWIRE -- Altimmune, Inc. Nasdaq: ALT, a clinical-stage biopharmaceutical company, today announced that Dr. Samuel Klein, William H. Danforth Professor of Medicine and Nutritional Science Director, Washington University School of Medicine, will deliver an oral presentation at the 82nd American Diabetes Association ADA Scientific Sessions, to be held in New Orleans, LA on June 3-7, 2022. Dr. Klein will present the results of Altimmunes recently completed Phase 1, first-in-human clinical trial of pemvidutide, an investigational GLP-1glucagon dual receptor agonist in development for the treatment of obesity and NASH. 